Enzalutamide with standard first-line therapy for metastatic hormone-sensitive prostate cancer: a plain language summary of the ENZAMET trial (ANZUP 1304)
Published in Future Oncology (Ahead of Print, 2025)
Related Articles
Exclusive: Leak reveals national plans to tackle A&E crisis
A raft of reforms NHS England and government are proposing to address the crisis in urgent and emergency care can be revealed, after a draft…
Opinion | Trump’s Imperial Presidency?
We may be heading to the outer limits of America’s system of checks and balances.
Pan-tumor analysis to investigate the obesity paradox in immune checkpoint blockade
Background Obesity is a risk factor for developing cancer but is also associated with improved outcomes after treatment with immune checkpoint inhibitors (ICIs), a phenomenon…
Skills Lab: Clinical Trial Methods — Focus on the Control Arm
Dr Bishal Gyawali discusses the methods section of clinical trial publications, focusing on potential issues with the control arm.
How AI can predict rugby injuries before they happen
Non-contact injuries are a persistent challenge in rugby union. But what if coaches could use AI to help foresee those injury risks?
Optimizing Public-Private Partnerships for Clinical Cancer Research A Workshop | National Academies
Learn more from the National Academies of Sciences, Engineering, and Medicine
Adobe Acrobat – college-report-cr240-outcome-measures-in-psychiatry.pdf
View this file, and add comments too.
Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone Induction in Newly Diagnosed Myeloma: Analysis of the MIDAS Trial
Key Points. Induction therapy with IsaKRD in the MIDAS study yielded the highest pre-transplant MRD-negativity rates ever reported in TE NDMM patientsThe f
